Cystinuria Treatment Market to Reach US$ 216.50 Million by 2030 at 4.80% CAGR; North America Leads with 40% Share – Key Players: Travere Therapeutics, Teva Pharmaceutical, Advicenne

Original Story Here

Cystinuria Treatment Market Overview

The global cystinuria treatment market reached US$164.20 million in 2024 and is expected to reach US$216.50 million by 2030, growing at a CAGR of 4.80% during the forecast period.

The market is growing steadily because more people are being diagnosed with cystinuria, a rare genetic condition that leads to frequent kidney stones. This increases the need for effective long-term treatments and disease management.

Growth is supported by increased awareness of rare diseases, advancements in drug treatments, and targeted therapies such as tiopronin, penicillamine, and captopril. Treatment helps prevent stone formation, reduce recurrence, and improve quality of life.

Minimally invasive procedures like extracorporeal shock wave lithotripsy and ureteroscopy are also improving outcomes. Ongoing research, higher healthcare spending, and better diagnostics continue to drive market expansion.

Key Developments

  • February 2026: Increased awareness and rising incidence boosted demand for treatments.
  • January 2026: Improved diagnostics enabled earlier detection and personalized care.
  • December 2025: Companies focused on developing new targeted therapies.
  • November 2025: Continued use of traditional therapies supported disease management.
  • October 2025: Investments in gene therapy and precision medicine increased.
  • September 2025: Growth driven by improved healthcare infrastructure worldwide.

Key Players

Travere Therapeutics, Inc. | Dr. Reddy’s Laboratories Ltd. | Advicenne | Teva Pharmaceutical Industries Ltd. | ANI Pharmaceuticals, Inc. | Viatris Inc. | AdvaCare Pharma | Camber Pharmaceuticals, Inc. | Bausch Health Companies Inc. | Panacea Biotec | Other

Market Drivers

  • Rising prevalence of cystinuria
  • Increasing kidney stone recurrence
  • Better diagnostics and early detection
  • Advancements in drug treatments
  • Higher healthcare spending
  • Focus on preventive care and diet
  • Growth in rare disease research

Industry Developments

  • New thiol-based drugs in development
  • Gene-based therapy research
  • More clinical trials
  • Improved diagnostic tools
  • Pharma and research collaborations
  • Combination therapies increasing
  • Expanded patient support programs

Regional Insights

  • North America (40%): Strong research and healthcare infrastructure
  • Europe (28%): Favorable regulations and awareness
  • Asia Pacific (20%): Fastest growth due to rising diagnosis and investment
  • Latin America (7%): Improving healthcare access
  • Middle East & Africa (5%): Gradual growth with expanding infrastructure

Key Segments

By Type

  • Cystinuria Type 1
  • Cystinuria Type 2
  • Cystinuria Type 3

By Drugs

  • Tiopronin (Thiola)
  • Penicillamine
  • Captopril
  • Others

By Route of Administration

  • Oral
  • Injectables

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Contact

DataM Intelligence
Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com